Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Memory-Like NK Cells

Phase 2Cell therapy

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Memory-Like NK Cells is one of 41 biologic programs targeting Memory. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

40

Competitors

Pipeline

Status by Indication[3][1]

Indication

MemoryActive, not recruiting

MemoryPhase 2

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Memory

#DrugCompanyPhaseTrials

Aricept

Myrbetriq

Ritalin

Inderal

WWyeth-Lederle Vaccines

Ambien

PPurdue Pharma LP

Intuniv

PPromius Pharma, LLC

Mifeprex

Nuvigil

NNuvo Research GmbH

Rilutek

AAzurity Pharmaceuticals

Bendopa

MMerz North America, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Active, not recruiting

Memory

NCT07274449

Clinical

Trials by Indication[1]

Memory1 trial

Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors

Active, not recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT07274449·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Memory-Like NK Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Memory-Like NK Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Memory-Like NK Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Related News